---

2012

ルーム内検索
全47件   1  2  3 次の20件>>
ID
トピック名
閲覧/投稿
最新投稿
作成
62 【基礎研究】Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 590 / 0
2013-01-10
KMF CRC
61 【臨床研究】Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium 582 / 0
2013-01-10
KMF CRC
60 【レビュー】Have drug combinations supplanted stem cell transplantation in myeloma? 575 / 0
2013-01-10
KMF CRC
59 【コメント】Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant 2,788 / 0
2012-12-04
KMF CRC
58 【基礎研究】 Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells 837 / 0
2012-12-04
KMF CRC
57 【基礎研究】Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. 633 / 0
2012-11-20
ルート 管理者
56 【基礎研究】Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. 589 / 0
2012-11-20
ルート 管理者
55 【臨床試験】A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. 640 / 0
2012-11-20
ルート 管理者
54 【基礎研究】Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopoietic stem and progenitor cells. 589 / 0
2012-11-20
ルート 管理者
53 【臨床試験】Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. 591 / 0
2012-11-20
ルート 管理者
52 【基礎研究】Addiction to c-MYC in multiple myeloma. 628 / 0
2012-11-20
ルート 管理者
51 【基礎研究】Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. 569 / 0
2012-11-20
ルート 管理者
50 【臨床試験】A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. 595 / 0
2012-11-20
ルート 管理者
49 【レビュー】Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. 1,994 / 0
2012-11-20
ルート 管理者
48 【臨床試験】Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase III PETHEMA/GEM study. 622 / 0
2012-11-20
ルート 管理者
47 【基礎研究】Clinical and prognostic role of annexin A2 in multiple myeloma. 1,216 / 0
2012-11-20
ルート 管理者
46 【基礎研究】Clonal competition with alternating dominance in multiple myeloma. 567 / 0
2012-11-20
ルート 管理者
45 【基礎研究】Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. 668 / 0
2012-11-20
ルート 管理者
44 【解説】Proteasome inhibitors in multiple myeloma: 10 years later. 829 / 0
2012-11-20
ルート 管理者
43 【臨床試験】A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. 630 / 0
2012-11-20
ルート 管理者
全47件   1  2  3 次の20件>>